Orbis Medicines ApS: Financial statements 2025
CVR: 42715646
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Orbis Medicines ApS (CVR 42715646) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -114,117,791 and a net result of DKK -136,526,045 compared with DKK -37,020,933 the year before. Equity in the 2025 report amounted to DKK 287,462,567. The solvency ratio was 94.6%. The company had 17 employees in the financial year.
- Gross Profit
- DKK -114,117,791
- Profit/Loss
- DKK -136,526,045
- Equity
- DKK 287,462,567
- Total Assets
- DKK 303,800,926
- Employees
- 17
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -114.1 mio. | -136.5 mio. | 287.5 mio. | 17 |
| 2024 | - | -51.6 mio. | -37 mio. | 127 mio. | 1 |
| 2023 | - | -25.6 mio. | -17.6 mio. | 68.9 mio. | 0 |
Official annual report
How creditworthy is Orbis Medicines ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Orbis Medicines ApS has published its annual report for 2024. Gross profit came to DKK -51,629,104, and the net result was DKK -37,020,933.
As of March 1, 2025, Marco Boorsma has joined the board of directors of Orbis Medicines ApS.
As of March 1, 2025, Goran Mikael Dolsten has joined the board of directors of Orbis Medicines ApS.
As of February 28, 2025, Marco Boorsma has left the board of directors of Orbis Medicines ApS.
As of February 1, 2025, Morten Døssing is registered as adm. dir. of Orbis Medicines ApS.
As of February 1, 2025, Søren Sylvester Skjærbæk has stepped down as director of Orbis Medicines ApS.
About Orbis Medicines ApS
Orbis Medicines ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Morten Døssing. The board consists of Goran Mikael Dolsten (chair), Alonso Ricardo Rodriguez, Edward Timothy Mathers and Marco Boorsma. The company is owned by Novo Holdings A/S, Forbion Ventures Fund VI Coöperatief U.A. and GF 2022 Global VC S.á r.l.. The company has 32 employees (2026). In 2025, the company reported a gross profit of DKK -114,117,791 and a net result of DKK -136,526,045 compared with DKK -37,020,933 the year before. Equity in the 2025 report amounted to DKK 287,462,567.